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Human metapneumovirus (hMPV) is a respiratory virus, first reported the year 2001.
Since then, it has been described as one of the main etiological agents that causes
acute lower respiratory tract infections (ALRTIs), which is characterized by symptoms
such as bronchiolitis, wheezing and coughing. Susceptible population to hMPV-infection
includes newborn, children, elderly and immunocompromised individuals. This viral
agent is a negative-sense, single-stranded RNA enveloped virus, that belongs to the
Pneumoviridae family and Metapneumovirus genus. Early reports—previous to 2001—
state several cases of respiratory illness without clear identification of the responsible
pathogen, which could be related to hMPV. Despite the similarities of hMPV with
several other viruses, such as the human respiratory syncytial virus or influenza virus,
mechanisms used by hMPV to avoid the host immune system are still unclear. In fact,
evidence indicates that hMPV induces a poor innate immune response, thereby affecting
the adaptive immunity. Among these mechanisms, is the promotion of an anergic state
in T cells, instead of an effective polarization or activation, which could be induced by
low levels of cytokine secretion. Further, the evidences support the notion that hMPV
interferes with several pattern recognition receptors (PRRs) and cell signaling pathways
triggered by interferon-associated genes. However, these mechanisms reported in hMPV
are not like the ones reported for hRSV, as the latter has two non-structural proteins
that are able to inhibit these pathways. Several reports suggest that viral glycoproteins,
such as G and SH, could play immune-modulator roles during infection. In this work, we
discuss the state of the art regarding the mechanisms that underlie the poor immunity
elicited by hMPV. Importantly, these mechanisms will be compared with those elicited by
other common respiratory viruses.
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INTRODUCTION
Human Metapneumovirus (hMPV) is a respiratory
virus discovered by van Den Hoogen et al. the year 2001,
in samples from Dutch children with acute lower respiratory
tract illness (ALRTI) (1). This virus is known to present a
similar pathology and clinical symptoms as the ones reported
for the human orthopneumovirus, previously known as
human respiratory syncytial virus (hRSV) (2). Clinical
symptoms of hMPV-infection can be manifested in both
upper and lower respiratory tracts with a predominance
for the latter. These symptoms are mainly associated with
the appearance of coughing, bronchitis, bronchiolitis and
respiratory manifestations related to the absence of airflow
(2–4). Symptomatology induced by hMPV-infection is caused
by a typical Th17-like immune response, characterized by the
secretion of interleukin (IL)-6 and TNF-α in the lungs (5). This
immune response is also accompanied by an inadequate Th2-like
profile, which is characterized by the early secretion of IL-4, IL-5,
IL-8, and other pro-inflammatory cytokines (6–8). Particularly,
the thymic stromal lymphopoietin (TSLP), a cytokine known
to impair T cell activation, promotes a delay in the Th1-like
immunity and triggers the secretion of cytokines related to a
Th2-like profile, resulting in high infiltration of neutrophils in
the lung of infected mice (9). This abnormal response, along
with an excessive mucus production by goblet cells, triggers the
collapse of the respiratory airways (3, 10). Infection with hMPV
in children under 2-years-old is a risk factor for the development
of asthma later in life, as reported for hRSV (11, 12). It has also
been reported that, in some of the most severe cases, hMPV
promotes chronic obstructive pulmonary disease (COPD) and
an exacerbated response, as asthma, in humans (10, 13). It has
been estimated that about 10–12% of the respiratory illness in
children are associated to hMPV, being considered as one of the
most prevalent viruses causing hospitalization in young children
(4, 14). It has also been described that hMPV is involved in
hospitalizations at a rate of 1 out of 1,000 children under the age
of 5 year; and 3 out of 1,000 infants under the age of 6 months.
Additionally, it has been reported that prevalence of hMPV
infection is equivalent to influenza virus and parainfluenza virus
types 1–3 (15).
HMPV belongs to the Pneumoviridae family and
Metapneumovirus genus. It has a negative-sense, single-
stranded RNA genome of about 13Kb of length, encoding 9
structural proteins that go as follows: 3
′
-N-P-M-F-M2-SH-G-
L-5
′
(Figure 1) (16). The different effects of these proteins on
the immune system of the host are not fully characterized. The
attachment G protein, one of the two proteins responsible for
viral entry, has been widely studied, as it exhibits a role in the
evasion of the immune response, inhibiting the interferon (IFN)
pathways (17). For hRSV, this IFN pathway inhibition has been
demonstrated to be caused by the non-structural proteins 1
and 2 (NS1 and NS2) (18). Remarkably, and as stated above,
hMPV genome does not encode for any homolog of these NS
proteins. Therefore, this shared ability to inhibit IFN pathway
observed in both viruses, in the case of hMPV, is associated with
the G glycoprotein, suggesting a possible gain of function for this
protein, as compared with hRSV.
Despite increased incidence of hMPV infections in the last
years and its impact on health care centers worldwide, neither
vaccines nor effective treatments are commercially available
to control or prevent infections caused by this viral agent.
This is mainly due to the unclear knowledge and lack of
characterization of the infection and evasion mechanisms of the
immune system used by hMPV. Nonetheless, a candidate vaccine
using a recombinant Mycobacterium bovis Bacillus Calmette-
Guerin (rBCG) that expresses the P protein of hMPV has
recently been developed (19). This rBCG candidate vaccine has
shown promising results in mouse studies, inducing a protective
adaptive immunity—both cellular and humoral—against hMPV-
infection with an effective viral clearance (19–21). In this
article we will discuss different evasion mechanisms developed
by hMPV to prevent the generation of an adequate immune
response and the role of different viral proteins involved in these
virulence mechanisms.
PERSISTENCE OF HMPV IN EPITHELIAL
CELLS
It has been described that hMPV is able to persist in respiratory
infected cells after the replicative viral cycle is completed. Indeed,
hMPV persistence has been demonstrated in infected mice
(22, 23). Measurement of plaque forming units (PFUs) from
homogenized lungs of hMPV-infected mice evidenced a biphasic
infection cycle, with a peak of viral particles at 7 days post-
infection (dpi) and a second peak at 14 dpi. Nevertheless, the
authors also reported the appearance of PFUs from the samples
obtained from lungs during 28 and 60 days post-infection (22).
Additionally, viral RNA was detected by Reverse-Transcription
quantitative Polymerase Chain Reaction (RT-qPCR) even after
180 days post-infection. These observations suggest that hMPV
may have developed mechanisms that allow its persistence inside
of the host cell, resisting viral clearance until, at least, 2 months
after the initial infection (22, 23).
Moreover, a study performed by Hamelin et al. found that
hMPV-infected mice exhibit a strong pulmonary inflammation
associated with airway obstruction (10). Further, higher viral
loads were found after 5 days of infection, and these titers were
still detected 12 days after, when homogenized lungs from these
mice were used to infect LLC-MK2 cells in vitro. Similarly,
detection of viral copy numbers from infected lung by RT-qPCR
indicated that the highest value was detected after 5 days of
the initial infection, with a considerable decrease after 21 days.
Interestingly, the number of copies of the viral genetic material
increased after 42 days of infection and it was still detectable
until day 154. All these evidences support the idea of a chronic
infection in mice. These results could suggest a relationship with
the development of asthma in children infected with this virus,
as chronic pulmonary disease is hallmark for the appearance of
these condition that could be probably be caused by a chronic
infection with this virus (11). However, further studies are require
to determine if such models of infection could represent the
complexity of hMPV infections in humans (10).
Despite the gaps of knowledge regarding hMPV persistence,
a possible mechanism of how this virus may survive in epithelial
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FIGURE 1 | Molecular description of hMPV and the role of viral proteins in the evasion of the immune response. Schematics of the hMPV viral particle in the center
and its genomic organization. In the left panel are depicted the viral proteins synthetized by hMPV, separated in two different groups: “surface proteins” and “internal
proteins.” The right panel describes the main roles of some viral proteins involved in the evasion of the immune response. The proteins M2.1 and M2.2 are expressed
only during the replicative viral cycle.
cells for such long periods of time has been recently suggested.
Typically, death of infected host cells implies a reduction in viral
replication and an increase in the capacity of antigen presentation
by immune cells. A study performed by Marsico et al. described
in human alveolar epithelial A549 cells that hMPV is able to
persist through the inhibition of the apoptosis machinery (24).
This effect was associated with an increase in the expression
of Bcl-2, an antiapoptotic factor from the Bcl-2 family, in the
surface of hMPV-infected cells after 14 days of infection. In
addition, the authors postulated a direct correlation between
cellular survival and viral replication, suggesting that hMPV
starts its infective cycle with a strong peak of replication and a
significant increase in cellular apoptosis, followed by a decrease
in viral infective rates, promoting a slow cellular proliferation,
overcoming apoptosis and inducing cell cycle arrest in G2/M
(24). On the other hand, hRSV-infection has been associated
with an early induction of Mcl-1 -another antiapoptotic factor
that belongs to the Bcl-2 family- along with more antiapoptotic
factors (Bcl-W, Bcl-xL) and pro-apoptotic factors (Bid, Bax,
Bak), which all could be mediated by the NF-κB pathway (25),
suggesting that hMPV could also be using others factor from the
Bcl-2 family.
ROLE AND EFFECT OF THE
HMPV-PROTEINS IN AVOIDING THE
IMMUNE RESPONSE
Currently, the mechanisms of immune evasion used by hMPV
are unclear. However, the ability of some hMPV structural
proteins to inhibit some cellular pathways required to enhance
viral infection have been described. Among these, the attachment
or G glycoprotein has the function to recognize and promote the
first interaction with the host (26). It has also been described that
the G protein has the ability to inhibit the IFN-I response not only
in vitro (17), but also in an in vivo model (27). The latter study
showed that the G protein is associated with the recruitment of
neutrophils into the alveolar space in lungs of mice infected with
hMPV (27). The authors propose that this phenomenon is due to
the inhibition of the IFN response, detecting important changes
in molecules involved in the recruitment of neutrophils such as;
CCL3, CCL4, VEGF, TNF, IL-17, and CXCL2 (27). Also, it has
been demonstrated that hMPV activates the TSLP pathway and,
therefore, promotes the recruitment of polymorphonuclear cells
(PMNs) that secrete cytokines such as IL-13 and IL-5 (9).
A study performed by Le Nouen et al. associated a lower
capacity of hMPV infected- human monocyte-derived dendritic
cells (MDDCs) to present hMPV antigens to naïve T cells
(28). This study described that hMPV-infected MDDCs showed
lower maturation levels in flow cytometry assays. Consequently,
this effect induced a poor T cell activation, as compared with
MDDCs infected with a mutant hMPV that lacked both SH
and G glycoprotein genes (1SHG). Remarkably, this effect was
not observed when a mutant virus deficient in either SH or G
genes was used (1SH or 1G, respectively) (28). The MDDCs
infected with 1SHG virus showed an increased maturation rate,
promoting the activation of naïve T cells into activated T CD4+
cells, with a Th1-like profile (28).
Interestingly, the infection rate detected in MDDCs was lower
than the one identified in epithelial cells. The G protein has
also been shown to induce enhanced viral replication in airway
epithelial cells (AECs), but poorly in MDDCs (28). However, an
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in vivo study using the 1G hMPV mutant virus, demonstrated
that the viral replication of this mutant was impaired, promoting
a small increase in the type I IFN secretion (27). Another study
showed that the 1SH hMPV mutant strain did not affect viral
replication capacity when compared to the WT virus, but it
did exhibit an inhibition of the NF-kB pathway in human lung
epithelial cells (29). The deletion of both viral G and SH genes is
related to an increase in the number of effective immunological
synapses between DCs stimulated by hMPV and memory CD4+
T cells, therefore promoting the activation of these memory
T cells. Altogether, it has been shown that G and SH proteins
might reduce the ability of hMPV-infected DCs to activate
CD4+ T cells, since both proteins are associated with decreased
internalization of the virus into DCs (28). The G protein of hRSV
has been described to modulate the host immune response in
several ways. It has been shown that hRSV-G protein induces a
biased Th2-like immune response in mice, although it can be
reverted by using anti-G protein monoclonal antibodies (30).
Also, hRSV-G protein can diminish the activation of DCs via
interaction with DC/L-SIGN (transmembrane proteins that
recognize mannose- and fucose-containing oligosaccharides),
which promotes phosphorylation of ERK1 and ERK2
in vitro (31).
Nevertheless, some studies suggest that G protein promotes
the inhibition of toll-like receptor 4 (TLR4) signaling in MDDCs,
affecting the type I IFN secretion (32). The expression of type I
IFN and several chemokines can be blocked by down-regulating
TLR4 with siRNA, demonstrating that TLR4 is important for the
activation of MDDCs induced by hMPV (32). In addition, it has
been described that the G protein is also able to inhibit cellular
responses induced by hMPV, by interfering with the TLR4-
dependent signaling and affecting the production of cytokines
and chemokines (32). Therefore, the G protein of this virus
negatively modulates the immune response of the host. A study
performed with TLR4-deficient mice conducted by Velayutham
et al. showed that TLR4 not only plays an important role
in the activation of the innate immune response to hMPV,
but also contributes to disease pathogenesis (33). Inflammatory
response and disease severity were seen to be diminished
in hMPV-infected mice lacking TLR4, which was related to
significantly lower levels of pro-inflammatory cytokines (TNF-
α, IL-1β, IL-6) and chemokines in these mice. Inflammatory
cells in BAL, lungs and lymph nodes were also significantly
reduced in TLR4-deficient mice when compared with WT mice.
Lastly, parameters like body weight loss, hyperresponsiveness
and airway obstruction associated with clinical disease severity
were reduced in TLR4-deficient mice (33). Similarly, immune
response to hRSV induces the activation of the NF-κB pathway
dependent on the expression of TLR4, however, the inflammatory
response of the airway is not dependent on TLR4 (34).
The negative regulation of the type I IFN signaling pathway
observed upon hMPV infection, can also be explained by the
activity of the SH protein of the virus. Indeed, the deletion
of hMPV SH protein is associated with an increase in the
production of IL-6, IL-8 and the expression of other genes
dependent of the NF-κB pathway (29). Furthermore, it has been
recently determined that SH inhibits the phosphorylation of
STAT1, impairing its subsequent signaling (35). Once the IFN-
α receptor (IFNAR) is activated, STAT1 is needed downstream
of the pathway for the expression of antiviral effector molecules
(36–38). The SH protein from hRSV has been shown to prevent
apoptosis in hRSV-infected cells, as this protein can inhibit TNF-
α-induced death and also inhibit NF-κB activation induced by
TNF-α (39). More recently, it has been proposed that hRSV-
SH protein could be part of a signaling pathway that induces
activation of inflammasomes, by increasing permeability and
disrupting membrane architecture, which could be associated
with a viral ion channel formation (40).
Although the G and SH are the most studied proteins
regarding hMPV capacities to evade immunity, other proteins
have also been associated to these processes. Among those, the
M2-2 protein has been shown to inhibit MAVS (mitochondrial
antiviral signaling), thus contributing to hMPV immune evasion,
silencing the cellular responses dependent on MAVS (41). Since
MAVS is needed for activation of NF-κB and IRF3, the inhibition
of this protein results in enhanced viral replication and cell
death, while its overexpression augments the production of IFN
(activated by NF-κB and IRF3) and results in an antiviral state
(42). NF-κB and IRF3 are activated by hMPV through TRAF5,
TRAF6, and TRAF3, which are recruited by MAVS, thus, when
suppressed by M2-2, the immune response dependent on MAVS
is also inhibited, as it has been recently described (43).
Moreover, a recent in vitro study indicated that DCs infected
with hMPV lacking the M2-2 gene produce a greater amount
of cytokines, chemokines and IFNs, suggesting that the M2-2
protein has an inhibitory role on the innate immune response
(44). In addition, in the same study, it was pointed out that
M2-2 is capable of inhibiting the expression of genes that are
dependent on MyD88 (myeloid differentiation protein response
88), an essential adapter for some TLRs, critical for the immune
responses of DCs (44). hRSV strains lacking the M2-2 protein
do not grow as efficiently as WT virus (45, 46). Also, it has been
suggested that this protein works regulating the RNA synthesis,
as infected cells with hRSV lackingM2-2 gene accumulate mRNA
beyond the levels detected on cells infected with WT virus (45).
The hRSV M2-2 gene has been deleted as an approach for the
development of vaccine against hRSV (RSV MEDI1M2-2) (46).
Little is known about the role of the M2-1 protein in hMPV
evasion mechanisms. However, this protein presents a critical
role in hMPV pathogenesis and viral replication (47, 48). One
possible characteristic suggested for the protein’s role is its Zinc
binding activity. Some studies suggest that mutations in this
zinc binding protein can affect the infective capacity of hMPV,
promoting an attenuated infection in cotton rats (47). The M2-
1 protein from hRSV has a transcriptional function, as it can
prevent early termination of the viral RNA transcription, which
requires the formation of the RdRp complex and the interaction
with RNA and the hRSV P protein. Remarkably, the hRSV M2-
1 protein increases the processivity of the viral RNA polymerase
(49, 50).
The matrix (M) protein is mainly associated with the assembly
of the hMPV viral particle (16). It is also known that this
protein promotes the production of inflammatory cytokines
in MDDCs, such as IL-1β, TNF-α, IL-6, and IL-8 (4, 51).
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Lastly, the retinoic acid inducible gene (RIG-I) can sense
hMPV infection and induce a type I IFN response, however,
the hMPV-B1 strain has been described to avoid this IFN
response thanks to the phosphoprotein (P), which prevents
RIG-I activation (52). The M protein from hRSV is essential
for viral replication and proliferation. This protein interacts
with the nucleocapsids under the plasma membrane and with
the envelope glycoproteins, suggesting participation in virus
assembly and inhibition of transcription (53). Mice infected
with hRSV lacking the M protein exhibited reduced weight loss,
viral titters, and pulmonary dysfunction, as compared to control
groups. Also, an important memory immune response is seen on
the M-null hRSV-infected mice (54).
More studies are needed to determine the interactions
between hMPV proteins and different host factors associated
with the immune response, in order to understand the immune
modulation during the infective process and pathogenesis, which
will improve the design of efficient therapies and prophylactic
approaches against this pathogen.
INEFFICIENT CYTOKINE PROFILE
SECRETION
Several studies have been performed to characterize the immune
response associated with hMPV infection—particularly, by
assessing the profile of secreted cytokines (55). It has been
reported that DCs obtained from mice can reduced their
migratory capacity, cytokine production, and CD4+ T cell
activation, when infected with hMPV, similarly as observed in
hRSV infections (56–61). However, the cytokine profile induced
by hMPV in humans is different from the cytokine profile
induced by hRSV or influenza virus (55).
The recognition of hMPV by the innate immune system
is associated with pattern recognition receptors (PRRs). This
recognition in the upper and lower respiratory tract is performed
by AECs, hMPV main target cells for infection, and by
phagocytic cells, such as DCs and macrophages, that express
PRRs and can recognize several pathogen-associated molecular
patterns (PAMPs) (62). These PAMPs include double-stranded
RNA and viral proteins produced during the replication
cycle. The activation of PRRs renders immune cells able to
promote the activation of several pro-inflammatory cytokines
and chemokines (62).
Recently, it has been reported that hMPV infection induces
the production of thymic stromal lymphopoietin (TSLP) as
an early response to the viral infection by AECs (9). This
upregulation induces an allergic-like innate immune response
that drives the expression of Th1- and Th2-like cytokine such
as TNF-α, IL-5, and IL-13, as a part of a late antiviral response
that eventually promotes an increase in polymorphonuclear
cells recruitment and an induction of mucus secretion in the
mouse lung (9). In turn, a pronounced pulmonary inflammatory
response and an increase in viral replication is produced upon
hMPV infection.
As hRSV and hMPV exhibit similar pathologies, they have
been continuously misdiagnosed among them (63). Accordingly,
it has been described that the cytokine profile is similar between
the two viruses, although with some differences. Indeed, Herd
et al. described that the transcript levels associated with Th1-
like cytokines (i.e., IL-12) and Th2-associated cytokines (i.e., IL-4
and IL-10) were significantly enhanced upon infectionwith either
hMPV or hRSV, when compared with the respective controls
in a BALB/c mouse model (64). However, levels of IL-12 were
significantly higher in hMPV-infected mice when compared with
hRSV-infected mice. This report also describes an increase in
the secretion of IFN-γ and IFN-β (both Th1-like cytokines),
along with MIP-1a and CXCL-10 (chemokines associated with
the activation of granulocytes, and the chemoattraction of
macrophages and T cells after the hMPV and hRSV infection)
(64). Moreover, several others signaling molecules, particularly
Mig, CXCL1,MIP-1β, and IP-10, are upregulated in infectedmice
when compared with non-infected animals.
Recently, in vitro studies performed by Tzannou et al.,
described that the immunodominant antigens of hMPV are
the F, N, M2-1, M and P proteins (65). These authors also
indicated that the polyclonal CD4+ T cells repertoire produced
during infection was mainly associated with the secretion of
IFN-γ, TNF-α, GM-CSF, and granzyme B. However, contrary
to what was described above, no secretion of IL-6 or IL-10 was
detected. Interestingly, mice models of hMPV-infection show
that CD8+ T cells, but not CD4+ T cells nor neutralizing
antibodies, are involved in the protection from reinfection. The
opposite phenomena is seen in the case of hRSV-infections,
where CD4+ T cells are shown to be required for protection
against reinfections (66).
An increase in the secretion of IFN-γ, IL-1β, IL-2, IL-4, and
IL-6 has been described in nasopharyngeal aspirates of children
infected with either hMPV or hRSV that exhibit also acute
respiratory tract infection symptoms; this in line with what has
been previously reported in some works with mouse model (67).
Remarkably, IL-2 and IL-1β secretions were higher in hMPV-
infected children, when compared to those infected with hRSV.
Likewise, IL-4 secretion was higher in hRSV-infected children,
as compared with hMPV-infected children. These findings may
imply that the robust Th2-like response that has previously been
observed and extensively characterized for hRSV is not exhibited
in a similar magnitude by hMPV (67). Moreover, the authors
indicate that, along with this IL-1β and IL-6 increase, a Th17-like
immune response associated with neutrophil-mediated asthma
could be elicited during hMPV infection (67).
A study performed in Argentina using samples from
newborns and children under 1-year-old, showed that low
levels of IL-1β, TNF-α, IL-6, IL-8, and IL-12 were detected
in samples from hMPV-infected children, as compared with
children infected with hRSV or influenza virus (55). This
study suggests that, despite the fact that infection caused by
hMPV shares similarities with those caused by hRSV—including
symptoms and pathology—hMPV induces significantly lower
levels of respiratory inflammatory cytokines, as compared
with the response observed in hRSV-infected children (55).
Interestingly, the data obtained in this study are different to those
obtained in a study performed by Jartti et al., where IL-8 levels
induced by hMPV were higher than the ones induced by hRSV
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(68). Considering all these, it is unclear how hMPV is able to
induce lung collapse in a similar way than hRSV.
It has been previously reported that many viruses are able
to induce the activation of the type-I IFN pathway (i.e., IFN-
α and IFN-β), promoting the proliferation and differentiation
of adaptive immunity cells (69). Particularly, IFN-α and IFN-
β bind to the IFNAR, prompting a signaling cascade that is
mainly associated with the phosphorylation of STAT1, and its
consequent dimerization with STAT2. This dimer is able to reach
the nucleus and activate the transcription of several anti-viral
genes that may promote viral clearance (69). In vitro studies have
reported that hMPV is able to avoid the type-I IFN pathway, as
it can modulate the first steps in the signaling cascade associated
with this network. As seen for other viruses, such as influenza A
virus (IAV) and hRSV, modulation of this pathway is performed
by several virulence factors (69).
It has been reported for IAV that hemagglutinin, one of
the surface proteins of this pathogen, is capable of inducing
degradation of IFNAR, therefore inhibiting autocrine signaling
associated with these molecules (69). Likewise, the NS1 protein
of hRSV is able to target STAT proteins so that they are degraded
through the proteasome, as described by Ramaswamy et al.
(70). Particularly, for hMPV it was recently reported that the
modulation of this pathway seems to be mainly through the
inhibition of STAT1 phosphorylation, induced by the SH protein
of this virus. The lack of phosphorylation of this protein seems to
be related to a desensitization of the IFNAR to IFN-α. Moreover,
other proteins have been associated with this modulation, such
as G and M2.2 proteins (41, 71). Therefore, even though hMPV
does seem to induce a similar response as the ones seen for other
respiratory viruses, the mechanisms associated to this induction
seem to be different (35, 55, 67).
Another possible reason to explain the IFN pathway inhibition
are the defective interfering (DI) RNA produced during the viral
replication process. It has been reported that an increase in the DI
RNA can promote type-I IFN secretion in epithelial cells, where
it was described that a high multiplicity of infection (MOI) of
hMPV promotes an increase in the DI RNA, but a low MOI
decreases the production of DI RNA and hence, an absence of
type-I IFN response is observed (72). This phenomenon has only
been identified in culture cell lines, such as A549 and Vero cells
(72). Remarkably, this strategy to activate the type I-IFN pathway
has been also described in other viruses, such as the Sendai
virus (SeV), Measles virus Edmonston strain (MeVEdm), and
hRSV (73).
TLRS AND THEIR EFFECTS OVER THE
IMMUNE RESPONSE INDUCED BY HMPV
TLRs are a type of receptor associated with the activation
of different pathways of the immune system, mainly the
innate immune system (74–78). This activation occurs by the
recognition of different pathogen associated molecular patterns
(PAMPs) that promote an intracellular signaling pathway in the
cell. As a consequence, cytokines and chemokines are secreted in
response to stimuli.
Some TLRs involved with hMPV-infection have been studied
(Figure 2), suggesting that the absence of TLR4 in mice infected
with hMPV results in a decrease in the production of cytokines,
FIGURE 2 | Toll-like receptors (TLRs) and their role in the evasion of the immune response induced by hMPV. The figure shows the effect of different TLRs in response
to hMPV-infection. (1) At the surface of the host cell, TLR4 (green receptor) is associated with the inhibition of type-I IFN. (2) In the intracellular space, TLR3 (red
receptor) is involved in the negative regulation of the MyD88/TRAF6/IKKα pathway. (3) The roles of TLRs 7 and 9 (purple and yellow receptor, respectively) in hMPV
infection are currently unclear.
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such as IFN-α/β, as well as reduced inflammatory response and
disease severity (33). Similarly, a reduction in lung inflammation
and disease severity has been reported in mice lacking MyD88
(79). The absence of MyD88 negatively affects the production of
cytokines and chemokines and the recruitment of DCs, CD4+
and CD8+ T cells into the lungs of infected animals (79). These
data indicate that both TLR4 and MyD88 are involved in the
pathogenesis of the disease, the pathogenic response against the
virus and in the lung inflammation.
Another role associated withMyD88 is its participation in one
of the two pathways involved in the production of type-I IFN in
response to in vitro hMPV infection, when the virus is detected by
TLR3 and TLR7. Once TLR3 detects hMPV, it is able to activate
IFN regulatory factor 3 (IRF3) through TRIF, whereas TLR7
activates IRF7 throughMyD88 (41, 52). RIG-I andMDA5 are two
helicases from the RIG-I-like receptor (RLR) family that induce
signaling downstream to MAVS after detecting viral dsRNA in
the cytosol (48, 56, 57). Subsequently, MAVS activates IRF3, and
this in turn activates the production of type-I IFN and the up-
regulation of IRF7 and NF-κB, thus producing proinflammatory
cytokines and type-III IFNs (80). The absence of MDA5 in
mutant mice is related with a more severe disease caused by
hMPV (i.e., increased pulmonary inflammation and cellular
infiltration, and a more sustained weight loss over time). This
phenomenon is accompanied by an increase in viral replication
and decreased production of type I-IFN, which suggests an
altered antiviral response (81).
In an epithelial cell model, hMPV elicits the expression of
both, RIG-I and MDA5, however, it has been suggested a more
important role for RIG-I, as its inhibition results in a negative
regulation of both downstream transcription factors NF-κB and
IRF (Figure 3). This in turn results in a diminished production
of IFN and pro-inflammatory cytokines, and an increase in viral
replication, which highlights the role of RIG-I contribution to an
antiviral state. This study also suggests thatMDA5 seems to play a
non-significant role in cellular responses induced by hMPV (80).
Similarly, during early hRSV-infection (6 h post-infection), viral
N protein colocalizes with RIG-I andMDA5, and later (12 h post-
infection) N protein appears in close proximity to MAVS and
MDA5, suggesting that the decreased IFN response -and thus the
inefficient innate response observed in the experiment- is due to
an interaction between the N protein andMAVS andMDA5 (82).
Once DCs have recognized the pathogen through their TLR7
and TLR9 receptors, the signaling pathways induce the activation
FIGURE 3 | Effects of hMPV proteins on signaling pathways. Once the viral particle has fused with the plasmatic membrane, the viral RNA is delivered to the
cytoplasm and recognized by MDA5 or RIG-I (PRRs), activating the IRF3 and NF-κB pathways through TRAF3, TRAF5, and TRAF6 after these factors are recruited by
MAVS. After the viral proteins are translated from viral RNA inside the host cell, the M2-2 viral protein can inhibit MAVS and thus, the MAVS-dependent immune
response. Viral particles are also detected by TLR4, initiating the signaling which ends in the translocation of both transcription factors IRF3 and NF-κB to the nucleus,
promoting an antiviral state and the expression of type-I IFN. The G viral protein interferes with the TLR4-dependent signaling, negatively modulating the immune
response of the host and promoting viral replication. The SH viral protein can inhibit the NF-κB signaling as well. Viral RNA detected inside endosomes by TLR3 and
TLR7/9 results in the phosphorylation of both transcriptional factors IRF3 and IRF7, and their entry to the nucleus to promote the expression of type-III IFN and
proinflammatory cytokines. The M2-2 viral protein inhibits the phosphorylation of IRF7, preventing its translocation to the nucleus. The SH viral protein induces the
same effect on IFNAR signaling by preventing the phosphorylation of STAT1.
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of genes encoding for IFN-α (83–86). The M2-2 protein has also
been proposed to be a potent negative regulator of the TLR7/9-
dependent production of IFN-α in pDCs, since it is suggested
that it is capable of inhibiting phosphorylation of Ser477-IRF7
induced by MyD88/TRAF6/IKKα (Figure 3) (87).
In addition, a study performed in neonatal mice showed
that the absence of IRF3 and IRF7 is a critical factor involved
in hMPV clearance. However, this response was only observed
when both transcription factors were absent. It was determined
through a KO mice model that the absence of IRF3 induced a
decrease in IFN-β, IFN-λ2/3, and IFN-γ secretion, although IFN-
α expression was not affected. Consequently, this triggered an
increase in the viral loads detected in the lungs (88). Regarding
IRF7, it was found that its absence decreased the expression
of only four cytokines, but that viral loads in the lungs were
not affected and a Th2-like profile was promoted with its
characteristic increase in the eosinophil population (88). IPS-1
(IFN-β promoter stimulator 1) levels correlated positively with
IFN-β secretion, and its absence resulted in an increase in IFN-
a4 secretion (88). This is similar to what was observed in the
IRF-7-lacking model, suggesting that IFN- α could likely be an
IPS-1/IRF3-independent activation pathway of TLR7-MyD88 in
plasmacytoid dendritic cells.
A recent study by Baños-Lara et al. showed a differential
miRNA pattern expression in Monocyte derived DCs (MoDCs)
induced by hMPV- and hRSV-infection. Therein, they report
that hMPV induces a higher expression of has-miR-185–5p, a
miRNA that affects different genes such as FOXO1, PDCD4 and
RECK, among others; but the effect in the dysregulation of these
genes is not reported (89). On the other hand, hRSV induces the
expression of miR-4448, that is associated with the Akt/mTOR
pathway, inhibiting apoptosis and, as a consequence, increasing
cell survivor (90).
CONCLUSION
hMPV is an emergent respiratory virus that each year
increases its incidence and burden. Furthermore, despite its
similarities with hRSV at a genomic and clinical level, the
immune response triggered by both viruses are not identical.
Likewise, the immune responses elicited in humans and
mouse models exhibit significant differences in the cytokine
secretion profile. In addition, hMPV mechanisms to escape the
immune system are mostly unknown and yet to be described,
although more studies regarding the understanding of this
viral agent are emerging. Currently, it is known that SH and
G glycoprotein are the most important proteins involved in
evasion of the immune response, promoting the inhibition
of an antiviral immune response triggered by type-I IFN.
Also, the modulation of different intracellular TLR involved
in the immune response against viral particles or intracellular
pathogens is clearly a mechanism that needs to be characterized
in detail. Remarkably, hamsters, mice, and even non-human
primates used as animal models of hMPV-infection are, in
different degrees, semi-permissive to viral infection (91), thus
it is highly important to perform more studies to determine
if such models are representative of an hMPV-infection in
humans.
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